Esperion Therapeutics to be acquired by ARCHIMED for $3.16 per share cash plus up-to-$100M CVRs

 

• Transaction values Esperion at up to approximately $1.1B including cash consideration and contingent value rights.
• CVR pays $40M if 2027 U.S. Nexletol/Nexlizet net sales exceed $350M under the definitive agreement.
• Additional $60M CVR payment triggered if Enbumyst U.S. sales top $160M by the end of 2030.

https://finviz.com/quote?t=ESPR&p=d